Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D Cohen

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Blood Cancer Discovery|November 22, 2022
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Nature Medicine|January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesJulie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Blood Cancer Discovery|November 22, 2022
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Nature Medicine|January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesJulie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Pageof 11